Vertex Pharmaceuticals VRTX
$547.09 +$4.59 (+0.85%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $548.00 +0.17%
Open$531.53
Prev close$542.50
Day range$531.53 – $548.76
Volume1.27M
Market cap$138.71B
P/E (TTM)35.2
Dividend yield–
Earnings
Average move on report day±4.9%last 15 reports
Closed higher6 of 1540% of the time
Best reaction+9.0%
Worst reaction-20.6%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 2 Nov 2026 | After Market | – | – | – |
| 2026/Q2 | 3 Aug 2026 | After Market | ±5.7% | +1.70% | Within range |
| 2026/Q1 | 4 May 2026 | After Market | ±6.0% | -1.28% | Within range |
| 2025/Q4 | 12 Feb 2026 | After Market | ±8.1% | +5.69% | Within range |
| 2025/Q3 | 3 Nov 2025 | After Market | ±6.9% | -1.02% | Within range |
| 2025/Q2 | 4 Aug 2025 | After Market | ±6.7% | -20.60% | Bigger than priced |
| 2025/Q1 | 5 May 2025 | After Market | ±4.6% | -10.03% | Bigger than priced |
| 2024/Q4 | 10 Feb 2025 | After Market | ±4.8% | -3.14% | Within range |
| 2024/Q3 | 4 Nov 2024 | After Market | ±5.3% | +5.73% | Bigger than priced |
| 2024/Q2 | 1 Aug 2024 | After Market | ±5.1% | -2.24% | Within range |
| 2023/Q4 | 5 Feb 2024 | After Market | ±4.7% | -2.98% | Within range |
| 2023/Q3 | 6 Nov 2023 | After Market | ±4.0% | -1.95% | Within range |
| 2023/Q2 | 1 Aug 2023 | After Market | ±3.6% | +3.07% | Within range |
| 2023/Q1 | 1 May 2023 | After Market | ±4.3% | +0.30% | Within range |
| 2022/Q4 | 7 Feb 2023 | After Market | ±4.1% | -4.93% | Bigger than priced |
| 2022/Q3 | 27 Oct 2022 | After Market | ±4.9% | +9.03% | Bigger than priced |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q2
By business line
Fundamentals
Latest reported quarter: Q2, ended Jun 2026
Revenue$3.33B+12.5% YoY
Operating profit$1.27B+9.9% YoY
Net profit$1.10B+6.5% YoY
Diluted EPS$4.31+8.0% YoY
Free cash flow$1.01B+9.3% YoY
Operating cash flow$1.13B
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin86.0%
Operating margin37.9%
Net margin35.0%
Return on equity23.5%
Return on assets17.1%
Return on invested capital19.5%
Current ratio3.19
Liabilities / assets26.2%
Cash & investments$7.85B
Total debt$1.98B
Net cash (debt)$5.87B
Free cash flow / sales30.2%
No comments yet — be the first to weigh in on VRTX.
Sign in to join the discussion.